Related Experiment Video
Updated: Oct 13, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
The Cox-Maze III procedure for atrial fibrillation associated with rheumatic mitral valve disease
1Department of Thoracic and Cardiovascular Surgery, College of Medicine, Seoul National University, Korea.
Insights
The Cox-Maze III procedure effectively restores sinus rhythm in patients with rheumatic mitral valve disease and atrial fibrillation, showing high success rates even in reoperations.
Area of Science:
- Cardiology
- Cardiac Surgery
- Electrophysiology
Background:
- Rheumatic mitral valve disease often coexists with atrial fibrillation (AF).
- Surgical outcomes for Cox-Maze III (CM-III) procedure in rheumatic mitral valve disease (RMVD) patients are less favorable than for AF alone.
- Assessing CM-III efficacy in this specific patient group is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of the Cox-Maze III procedure when combined with rheumatic mitral valve surgery.
- To determine the success rate of restoring normal sinus rhythm in patients with AF and RMVD.
- To analyze operative risks and long-term outcomes, including atrial contractility.
Main Methods:
- Retrospective analysis of 75 patients undergoing CM-III and rheumatic mitral valve procedures (April 1994 - December 1997).
- Included 14 reoperation cases due to prosthetic valve failure.
- Follow-up averaged 30 months, assessing sinus rhythm restoration and atrial contractility via echocardiography.
Main Results:
- High sinus conversion rate of 90.4% (66/73 survivors) was achieved.
- In-hospital mortality was 2.7% (2/75).
- Both right and left atrial contractility were restored, though left atrial contractility recovery was slower and less frequent.
Conclusions:
- The Cox-Maze III procedure is a safe and effective treatment for atrial fibrillation in patients with rheumatic mitral valve disease.
- The procedure demonstrates a high sinus conversion rate and acceptable operative risk, even in reoperative cases.
- Restoration of atrial contractility is achievable, supporting the procedure's utility in this complex patient population.
Background:
The surgical results of the Cox-Maze III procedure (CM-III) for atrial fibrillation (AF) associated with rheumatic mitral valve (MV) disease are not as good as the results from surgery for AF alone.
Methods:
To assess the efficacy and safety of the CM-III in AF associated with rheumatic MV disease, we retrospectively analyzed 75 patients who underwent the CM-III combined with a rheumatic MV procedure between April 1994 and December 1997. Fourteen cases were reoperations because of prosthetic valve failure.
Results:
Mean aortic cross-clamp (ACC) times and cardiopulmonary bypass (CPB) times were 151+/-43 and 251+/-73 min, respectively. Concomitant procedures were mitral valve replacement (MVR) in 25 patients, MVR and aortic valve replacement (AVR) in 14 patients, MV repair in 10 patients, MVR and tricuspid annuloplasty (TAP) in 6 patients, MVR and AV repair in 3 patients, MVR and coronary artery bypass grafting (CABG) in 2 patients, MVR and AVR and CABG in 1 patient, redo-MVR in 8 patients, redo-MVR and TAP in 4 patients, and redo-MVR and redo-AVR in 2 patients. There were two in-hospital mortalities (2 of 75, 2.7%). Seventy-three survivors were followed for a mean duration of 30+/-13 months (12-56 months). Normal sinus rhythm was restored in 90.4% (66 of 73). Three patients remained in AF and 2 patients were in junctional rhythm. Permanent pacemakers were implanted in 2 patients due to sick sinus syndrome. Right atrial (RA) contractility was demonstrable in 100% (66 of 66) and left atrial (LA) contractility in 62.1% (41 of 66) of the patients in the latest follow-up echocardiography. RA and LA contractilities were restored a mean 69+/-93 and 126+/-136 days after the operation, respectively. LA contractility was restored significantly later at a lower rate than RA contractility in rheumatic MV disease. There were no differences in ACC time, CPB time, incidence of postoperative bleeding complications, and sinus conversion rates between non-redo and redo cases in spite of the significantly longer duration of preoperative AF in redo cases (p<0.05).
Conclusions:
The CM-III for AF associated with rheumatic MV disease demonstrated a high sinus conversion rate with acceptable operative risk even in cases of reoperation.
More Related Videos
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Related Concept Videos
Mitral Regurgitation I: Introduction
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation III: Medical Management
Mitral Stenosis I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Stenosis III: Medical Management